Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in c...

Descripción completa

Detalles Bibliográficos
Autor principal: Peterson, Mary E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699701/
https://www.ncbi.nlm.nih.gov/pubmed/23686401
http://dx.doi.org/10.1007/s00520-013-1826-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699701/
https://www.ncbi.nlm.nih.gov/pubmed/23686401
http://dx.doi.org/10.1007/s00520-013-1826-3

Ejemplares similares